MYMD VS JNJ Stock Comparison

Performance

MYMD
10/100

MYMD returned -82.67% in the last 12 months. Based on SPY's performance of -12.16%, its performance is below average giving it a score of 10 of 100.

JNJ
73/100

JNJ returned -15.84% in the last 12 months. Based on SPY's performance of -20.60%, its performance is above average giving it a score of 73 of 100.

Technicals

MYMD
25/100

MYMD receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.

JNJ
14/100

JNJ receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Profit

MYMD
10/100

Out of the last 20 quarters, MYMD has had 0 profitable quarters and has increased their profits year over year on 1 of them.

JNJ
74/100

Out of the last 20 quarters, JNJ has had 19 profitable quarters and has increased their profits year over year on 9 of them.

Volatility

MYMD
40/100

MYMD has had a lower than average amount of volatility over the last 12 months giving it a score of 39 of 100.

JNJ
43/100

JNJ has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Analyst Price Targets

MYMD

"Analyst Price Targets" not found for MYMD

JNJ
63/100

23 analysts offer 12-month price targets for JNJ. Together, they have an average target of 176.5, the most optimistic target put JNJ at 205 within 12-months and the most pessimistic has JNJ at 90.

Sentiment

MYMD

"Sentiment" not found for MYMD

JNJ
72/100

JNJ had a bullish sentiment score of 71.87% across Twitter and StockTwits over the last 12 months. It had an average of 205.31 posts, 3,341.61 comments, and 16,552.61 likes per day.

Earnings

MYMD

"Earnings" not found for MYMD

JNJ
100/100

JNJ has missed earnings 0 times in the last 20 quarters.

Dividend

MYMD

"Dividend" not found for MYMD

JNJ
100/100

JNJ's most recent dividend was $0.90 per share, based on a share price of $145.60. It was a payout ratio of 61.39% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

MyMD Pharmaceuticals, Inc. Common Stock (DE) Summary

Nasdaq / MYMD

Healthcare

Biotechnology

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Johnson & Johnson Summary

New York Stock Exchange / JNJ

Healthcare

Drug Manufacturers - General

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Power up your portfolio